272 related articles for article (PubMed ID: 31493843)
21. Estimating the effect of HIV on cervical cancer elimination in South Africa: Comparative modelling of the impact of vaccination and screening.
Boily MC; Barnabas RV; Rönn MM; Bayer CJ; van Schalkwyk C; Soni N; Rao DW; Staadegaard L; Liu G; Silhol R; Brisson M; Johnson LF; Bloem P; Gottlieb S; Broutet N; Dalal S
EClinicalMedicine; 2022 Dec; 54():101754. PubMed ID: 36583170
[TBL] [Abstract][Full Text] [Related]
22. Planning for human papillomavirus (HPV) vaccination in sub-Saharan Africa: a modeling-based approach.
Tracy JK; Schluterman NH; Greene C; Sow SO; Gaff HD
Vaccine; 2014 May; 32(26):3316-22. PubMed ID: 24731734
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study.
Xia C; Xu X; Zhao X; Hu S; Qiao Y; Zhang Y; Hutubessy R; Basu P; Broutet N; Jit M; Zhao F
BMC Med; 2021 Mar; 19(1):62. PubMed ID: 33653331
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia.
Shi JF; Qiao YL; Smith JS; Dondog B; Bao YP; Dai M; Clifford GM; Franceschi S
Vaccine; 2008 Aug; 26 Suppl 12():M53-9. PubMed ID: 18945414
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
26. Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study.
Jansen EEL; de Kok IMCM; Kaljouw S; Demirel E; de Koning HJ; Hontelez JAC
BMC Med; 2022 Nov; 20(1):433. PubMed ID: 36352410
[TBL] [Abstract][Full Text] [Related]
27. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Kaló Z
BMC Public Health; 2012 Oct; 12():924. PubMed ID: 23110361
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
30. Modelling cervical cancer elimination using single-visit screening and treatment strategies in the context of high HIV prevalence: estimates for KwaZulu-Natal, South Africa.
Rao DW; Bayer CJ; Liu G; Chikandiwa A; Sharma M; Hathaway CL; Tan N; Mugo N; Barnabas RV
J Int AIDS Soc; 2022 Oct; 25(10):e26021. PubMed ID: 36225139
[TBL] [Abstract][Full Text] [Related]
31. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
33. The future of cervical cancer prevention: human papillomavirus vaccines.
Cadman L
J Fam Health Care; 2008; 18(4):131-2. PubMed ID: 18754553
[TBL] [Abstract][Full Text] [Related]
34. Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis.
Messoudi W; Elmahi T; Nejjari C; Tachfouti N; Zidouh A; Saadani G; Moriña D; Diaz M
J Med Econ; 2019 Nov; 22(11):1153-1159. PubMed ID: 31135231
[No Abstract] [Full Text] [Related]
35. Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China.
Liu YJ; Zhang Q; Hu SY; Zhao FH
BMC Cancer; 2016 Feb; 16():164. PubMed ID: 26919850
[TBL] [Abstract][Full Text] [Related]
36. Cervical cancer elimination in Italy: Current scenario and future endeavors for a value based prevention.
Calabrò GE; Riccardi MT; D'Ambrosio F; Castagna C; Sapienza M; Millevolte R; Pellacchia A; Ricciardi R; de Vincenzo RP; de Waure C
Front Public Health; 2022; 10():1010237. PubMed ID: 36530690
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
38. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
[TBL] [Abstract][Full Text] [Related]
39. The budget impact of cervical cancer screening using HPV primary screening.
Wright T; Huang J; Baker E; Garfield S; Hertz D; Cox JT
Am J Manag Care; 2016 Mar; 22(3):e95-105. PubMed ID: 26978241
[TBL] [Abstract][Full Text] [Related]
40. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study.
Simms KT; Hanley SJB; Smith MA; Keane A; Canfell K
Lancet Public Health; 2020 Apr; 5(4):e223-e234. PubMed ID: 32057317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
